Meeting
2020 ASCO Virtual Scientific Program
Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).
Authors
Matti S. Aapro
Clinique de Genolier, Genolier, Switzerland
Matti S. Aapro , Marika Chrápavá , Razvan-Ovidiu D. Curca , Laurentia Gales , Alexandru Calim Grigorescu , Bára Karlínová , Renata Kellnerová , Edgar Petru , Adam Pluzanski , Maryna Rubach , Guenther G. Steger , Petra Tesarova , Nicolay Yordanov , Anna Walaszkowska-Czyz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12083)
DOI
10.1200/JCO.2020.38.15_suppl.12083
Abstract #
12083
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4.
First Author: Rudolph M. Navari
Poster
2020 ASCO Virtual Scientific Program
Antiemetic prophylaxis with NEPA: Final results of the German AKYPRO study.
First Author: Joerg Peter Schilling
Poster
2016 ASCO Annual Meeting
Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.
First Author: Kunihiro Matsuzaki
Poster
2013 ASCO Annual Meeting
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
First Author: Matti S. Aapro